ResMed launches S9 sleep apnoea therapy platform in Europe
February 23, 2016
Sleep apnoea is one of the more common, and yet highly undiagnosed, sleep disorders. The condition causes the sufferer to stop breathing throughout the night. There are three types of sleep apnoea; obstructive, mixed and central. Obstructive sleep apnoea (OSA) is the most common and is marked by the collapse or obstruction of the airway during sleep. The new S9 system treats OSA while also detecting central sleep apnoea and reporting a central apnea index for follow-up by providers and physicians.
A new study published in Science Translational Medicine, shows that it is very hard to catch up on lost sleep, and that the fatigue that follows interrupted sleep presents safety risks in traffic and at the workplace. A person with untreated sleep apnoea does not have the opportunity to catch up on lost sleep since the condition is a daily occurrence.
In addition to road and workplace accidents, the condition is responsible for contributing to extreme sleepiness, nodding off during the day, inability to perform optionally at work, elevated levels of blood pressure, heart disease, diabetes, episodes of stroke, and depression. While many people perceive snoring as a common harmless problem, it can be a clear sign of this serious condition.
SOURCE ResMed